Research Analysts’ Recent Ratings Changes for Medpace (MEDP)

A number of firms have modified their ratings and price targets on shares of Medpace (NASDAQ: MEDP) recently:

• 2/18/2026 – Medpace was upgraded by analysts at TD Cowen from a “sell” rating to a “hold” rating. They now have a $419.00 price target on the stock, down previously from $462.00.
• 2/13/2026 – Medpace was upgraded by analysts at Jefferies Financial Group Inc. from a “hold” rating to a “buy” rating. They now have a $560.00 price target on the stock.
• 2/11/2026 – Medpace had its “market perform” rating reaffirmed by analysts at BMO Capital Markets.
• 2/11/2026 – Medpace was given a new $582.00 price target on by analysts at Mizuho.
• 2/11/2026 – Medpace was given a new $460.00 price target on by analysts at BMO Capital Markets.
• 2/11/2026 – Medpace had its price target lowered by analysts at Barclays PLC from $525.00 to $500.00. They now have an “underweight” rating on the stock.
• 2/11/2026 – Medpace had its price target lowered by analysts at Leerink Partners from $575.00 to $485.00. They now have a “market perform” rating on the stock.
• 2/11/2026 – Medpace had its price target lowered by analysts at Truist Financial Corporation from $555.00 to $539.00. They now have a “hold” rating on the stock.
• 2/10/2026 – Medpace was upgraded by analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating. They now have a $564.00 price target on the stock.
• 1/28/2026 – Medpace had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 1/17/2026 – Medpace was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 1/12/2026 – Medpace was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 1/9/2026 – Medpace was given a new $660.00 price target on by analysts at Mizuho.

Insider Activity

In related news, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares in the company, valued at approximately $16,751,625. The trade was a 42.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kevin M. Brady sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the completion of the sale, the chief financial officer directly owned 6,000 shares in the company, valued at $3,542,100. This trade represents a 33.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 226,603 shares of company stock valued at $137,084,658. 20.30% of the stock is currently owned by insiders.

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.